PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424018
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424018
The global gRNA market size is expected to reach USD 2,357.17 million by 2032, according to a new study by Polaris Market Research. The report "gRNA Market Share, Size, Trends, Industry Analysis Report, By Product & Services (Products, Custom gRNA Synthesis Services), By gRNA Type, By Application, By End-use, By Region, And Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The market is poised for future growth, driven by the escalating investments from biotechnology and pharmaceutical companies in R&D activities. The creation of user-friendly and cost-effective gRNA synthesis kits and services has democratized access to CRISPR-Cas9 technology, catering to researchers across various expertise levels. The ongoing exploration of new applications for CRISPR-Cas9 contributes to the sustained demand for gRNA.
The increasing adoption of NGS is a significant catalyst for market growth. The widespread use of NGS technologies equips researchers with advanced tools for genomic analysis & manipulation. NGS enables the efficient sequencing of genetic material at high throughput, offering a rapid and cost-effective means of examining entire genomes. This efficiency is particularly crucial for gRNA applications, streamlining the identification and validation of target genes for genetic manipulation. This precision is essential in crafting gRNAs with high specificity using CRISPR/Cas systems.
Moreover, the introduction of new final gRNA products has the potential to stimulate innovation. For instance, in October 2023, Synthego, provider of IND-enabling gRNAs. This groundbreaking offering represents a significant progression in the CRISPR-based cell & gene therapy preclinical pipeline by furnishing researchers with meticulously designed, high-quality gRNAs tailored for GLP-regulated preclinical & IND-enabling studies.
Expanding the production volume may pose difficulties and could be constrained by the accessibility of suitable reagents, materials, and equipment. Irrespective of whether the therapy is autologous or allogeneic, a significant challenge lies in transitioning from manual processes to commercially automated manufacturing. This shift necessitates achieving uniformity throughout the entire process and ensuring compliance with regulations. For instance, the shortage of viral vectors in the capacity for cell and gene therapy is estimated to exceed 500%.
The research use segment dominated the market, primarily due to ongoing clinical trials and molecular research purposes
The genomic engineering segment held the largest share due to advances in genomic and proteomics
Pharmaceutical companies garnered the largest share due to the adoption of gRNA in personalized therapies
Asia Pacific will grow rapidly, primarily due to presence of unmet medical needs and innovations in the sector
The market players include Agilent Technologies, Horizon Discovery, Jena Bioscience, Merck, Synbio Technologies, Synthego, & Takara Bio Inc.
Polaris Market Research has segmented the gRNA market report based on product and services, gRNA type, application, end use, and region: